UPDATED: Teen meningitis B vax successful in Phase II

While there are routine vaccinations against meningococcal meningitis C, there is currently no shot to protect against meningitis B, a serious infection that can lead to brain damage and can result in blood poisoning so severe that arms and legs have to be amputated. Teams of researchers around the world are working on meningitis vaccines, and in the latest research a team from Australia has triggered an immune response in a Phase II trial of Pfizer's ($PFE) vaccine in teenagers.

The vaccine, known as MnB rLP2086 or PF-05212366, is in Phase II development and is designed to protect against meningitis B caused by 8 strains of invasive meningococcus serogroup B strains. It targets lipoprotein 2086, which is on the surface of the bacteria. In the study, the vaccine had few side effects and triggered a response against 90 percent of the strains tested in the vaccinated teenagers.

"The development of a vaccine to protect against multiple strains of meningococcal B is particularly important in Western Australia and in many regions of Europe and North America where this particular type of meningococcal disease is most prevalent," Associate Professor Peter Richmond, from the University of Western Australia, said. "This is the last major cause of meningitis for which we don't have a vaccine so we are very excited about the progress towards developing a safe and effective vaccine."

The study was published in the Lancet Infectious Diseases. The groups most at risk of contracting meningitis B are children between one month and one year and teenagers, and Pfizer is targeting adolescents in the research for this vaccine. The next step will be to test the vaccine in larger groups of different ages. According to the U.K.'s Daily Mail, the vaccine could be available in 5 years--watch this space to see if that wish comes true.

- read the press release
- see the abstract
- check out the article in the Daily Mail

Editor's Note: This story has been updated to reflect Pfizer's research focus on adolescents for this vaccine

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.